Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

A new jab, which will help prevent HIV transmissions, has been described as a ‘game changer’ by an LGBT charity in Northern ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

The city's axess sexual health service is piloting a new online platform that will deliver preventative HIV medication PrEP direct to patients without the need for them to have an in-person ...

In April 2025, we published a story with the headline: "Haunted by hopelessness: 12 Zambians share their stories as HIV drugs run out." It looked at the impact of President Trump's cuts to foreign aid ...